Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.58 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941844 | 1.00 | CA12 (0.58) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL6198418 | 0.89 | ALDH1A1 (0.55) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL4532625 | 0.88 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL6197423 | 0.86 | CA12 (0.51) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL29757375 | 0.85 | CA12 (0.57) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL3441071 | 0.85 | CA12 (0.57) | CA12BRD4BRPF1CA9KAT2B | |
| Hydrochloric Acid SCHEMBL29387018 | 0.83 | CA12 (0.55) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL585623 | 0.81 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL1807117 | 0.81 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL9688318 | 0.81 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398940-B1 | HIGH STRESS RESISTANT PLANT GROWTH REGULATOR AND PREPARATION METHOD AND USE THEREOF | CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES (CN) | 2022-06-22 | — | — | EP | disclosed |
| EP-3398940-B1 | HIGH STRESS RESISTANT PLANT GROWTH REGULATOR AND PREPARATION METHOD AND USE THEREOF | CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES (CN) | 2022-06-22 | — | — | EP | disclosed |
| US-11076597-B2 | High stress resistant plant growth regulator and preparation method and use thereof | CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES (CN) | 2021-08-03 | — | — | US | disclosed |
| US-11076597-B2 | High stress resistant plant growth regulator and preparation method and use thereof | CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES (CN) | 2021-08-03 | — | — | US | disclosed |
| CN-106749044-B | ABA analogue for enhancing plant stress resistance | 中国科学院上海生命科学研究院 | 2020-04-21 | — | — | CN | disclosed |
| US-20190000084-A1 | HIGH STRESS RESISTANT PLANT GROWTH REGULATOR AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES (CN) | 2019-01-03 | — | — | US | disclosed |
| US-20190000084-A1 | HIGH STRESS RESISTANT PLANT GROWTH REGULATOR AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES (CN) | 2019-01-03 | — | — | US | disclosed |
| EP-3398940-A1 | HIGH STRESS RESISTANT PLANT GROWTH REGULATOR AND PREPARATION METHOD AND USE THEREOF | Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences (CN) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017137742-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
| WO-2016022915-A1 | 6-SULFONYLAMINO QUINOLINE COMPOUNDS AS PLANT GROWTH REGULATORS | THE REGENT OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-11 | — | — | WO | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000084-A1 | HIGH STRESS RESISTANT PLANT GROWTH REGULATOR AND PREPARATION METHOD AND USE THEREOF | BOLA2; BOLA2B, MYB, PPA1 | CA12 4510/4885BRD4 1177/4885BRPF1 388/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | CA12 1203/4885BRD4 697/4885BRPF1 2923/4885 |
| US-11076597-B2 | High stress resistant plant growth regulator and preparation method and use thereof | BOLA2; BOLA2B, MYB, PPA1 | CA12 4510/4885BRD4 1177/4885BRPF1 388/4885 |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | VCAM1, EPCAM, ICAM1 | CA12 268/4885BRD4 2641/4885BRPF1 3593/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | CA12 889/4885BRD4 15/4885BRPF1 1789/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CA12 35/4885BRD4 1958/4885BRPF1 4264/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | CA12 166/4885BRD4 2562/4885BRPF1 3872/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | CA12 1232/4885BRD4 22/4885BRPF1 1791/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CA12 35/4885BRD4 1958/4885BRPF1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.